"The Company believes the “full hold” will be removed after we adequately respond to the FDA’s comments and incorporate the FDA’s specific guidance as it relates to the proposed protocol.
The Company believes the proposed HIV study will allow the Company to further establish leronlimab’s mechanism of action in a cost-effective manner, and is currently working to incorporate the FDA’s feedback and submit an amended protocol as soon as practicable. The Company expects to submit a revised protocol to the FDA in January 2024.
Way to go Dr. J. When you are one of the world's leading figures on HIV for 30+ years, you get the ear and attention of the FDA.
'23 the year of the pivot, '24 the year of new development and partnership(s) and NIH assistance...maybe some darpa monies?
What a great time to be around hey???
$CYDY$ Yes, leronlimab
Bullish
News 
Market Data 
Discover 
AI
